Drug Trial Radar · NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
142
Actual
Start
Jan 29, 2025
Primary completion
Jun 26, 2026
Study completion Aug 5, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Conditions
- Diabetes Mellitus, Type 2
- Diabetic Peripheral Neuropathy
Interventions
CagriSema (Cagrilintide B and Semaglutide I)Drug
Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Drug
Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)Time frame: From baseline (week 0) to end of treatment (week 32)
Locations
55 sites in 7 countries. Site status is shown where the registry gives one.
eStudySite
La Mesa, California
Linda Vista Health Care Ctr
San Diego, California
My Preferred Research
Miami, Florida
New Horizon Research Center
Miami, Florida
Renstar Medical Research
Ocala, Florida
Renstar Medical Research
Ocala, Florida
Foot & Ankle Center of Illinois
Springfield, Illinois
Velocity Clinical Research Rockville
Rockville, Maryland
Amicis Centers of Clinical Research
St Louis, Missouri
DM Clinical
Albuquerque, New Mexico
Southgate Medical Group, LLP
West Seneca, New York
Piedmont Healthcare/Research
Statesville, North Carolina
Lillestol Research LLC
Fargo, North Dakota
Oregon Health & Science University
Portland, Oregon
Clinical Res Collaborative
Cumberland, Rhode Island
DM Clinical
Houston, Texas
Radiance Clinical Research
Lampasas, Texas
DM Clinical Research
San Antonio, Texas
DM Clinical
San Antonio, Texas
Velocity Clinical Research Portsmouth
Suffolk, Virginia
G.A. Research Associates Ltd.
Moncton, New Brunswick, Canada
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada
Centricity Clinical Research Burlington
Burlington, Ontario, Canada
Centricity Research Etobicoke Endocrinology
Etobicoke, Ontario, Canada
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, Canada
Diabetes Heart Research Centre
Toronto, Ontario, Canada
Ctr de Med Metab de Lanaudiere
Terrebonne, Quebec, Canada
Aarhus Universitetshospital, Steno Diabetes Center Aarhus
Aarhus N, Denmark
Steno Diabetes Center Nordjylland
Gistrup, Denmark
Steno Diabetes Center Copenhagen
Herlev, Denmark
Kolding Sygehus Karkirurgi
Kolding, Denmark
Steno Diabetes Center Odense
Odense C, Denmark
Les Hopitaux de Chartres-Hopital Louis Pasteur
Le Coudray, France
Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu
Le Creusot, France
Aphp-Hopital La Pitie Salpetriere
Paris, France
Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque
Pessac, France
Centre de Recherche Clinique Portes Du Sud
Vénissieux, France
Haukeland Universitetssykehus
Bergen, Norway
Sykehuset Innlandet HF Hamar
Hamar, Norway
Oslo universitetssykehus, Ullevål
Oslo, Norway
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.